CAPR
Capricor Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.40
+1.29%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$546.51M
MomentumView details →
1D Return
+1.29%
YTD Return
−67.03%
RSI (14)
49.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$546.51M
RSI (14)
49.7
MomentumView details →
1D Return
+1.29%
YTD Return
−67.03%
SummaryUpdated Jun 1, 2026
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company founded in 2005 and headquartered in San Diego, California. The company went public in 2007 and focuses on developing transformative cell and exosome-based therapeutics for treating various diseases and disorders. Capricor is primarily known for its lead candidate <b>deramiocel</b> (formerly CAP-1002), an allogeneic cardiac-derived cell therapy that has completed Phase III clinical trials for treating late-stage Duchenne muscular dystrophy (DMD). The company has submitted a Biologics License Application (BLA) to the FDA for deramiocel, with a priority review PDUFA date of August 31, 2025.
Similar companies
Latest newsMore news →
Capricor Therapeutics shares rose 3.48% to $10.26 after an analyst raised the price target to $25 from $2.3d agoThe U.S. FDA extended the PDUFA target action date for Capricor Therapeutics' deramiocel Biologics License Application to November 22, 2026, as it continues review following submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication.11d agoA class action lawsuit was filed against Capricor Therapeutics, Inc. for alleged violations of U.S. securities laws, and the DJS Law Group is reminding investors of their rights to seek lead plaintiff appointment.12d ago